(Post-pandemic Era)-Global Radiopharmaceutical (Oral Route) Market Segment Research Report 2022
- Published Date: 2022-04-19
- Report ID: 128252
- Pages: 175
-
Format:
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Beijing Yanjing Bizhi Information Consulting Co., Ltd. XYZResearchreleased the Global Radiopharmaceutical (Oral Route) Market Segment Research Report 2022, which aims to sort out the development status and trends of the Radiopharmaceutical (Oral Route) industry at home and abroad, estimate the overall market scale of the Radiopharmaceutical (Oral Route) industry and the market share of major countries, analyze the development potential of each segment of the Radiopharmaceutical (Oral Route) industry, and study and judge the downstream market demand of Radiopharmaceutical (Oral Route) through systematic research, Analyze the competition pattern of Radiopharmaceutical (Oral Route), so as to help solve the pain points of various stakeholders in Radiopharmaceutical (Oral Route) industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Radiopharmaceutical (Oral Route) Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Radiopharmaceutical (Oral Route) Market
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Major Type of Radiopharmaceutical (Oral Route) Covered in XYZResearch report:
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Application Segments Covered in XYZResearch Market
Oncology
Cardiology
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Radiopharmaceutical (Oral Route) Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Radiopharmaceutical (Oral Route) Market by Value
2.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Type
2.2.2 Global Radiopharmaceutical (Oral Route) Market by Value (%)
2.3 Global Radiopharmaceutical (Oral Route) Market by Production
2.3.1 Global Radiopharmaceutical (Oral Route) Production by Type
2.3.2 Global Radiopharmaceutical (Oral Route) Market by Production (%)
3. The Major Driver of Radiopharmaceutical (Oral Route) Industry
3.1 Historical & Forecast Global Radiopharmaceutical (Oral Route) Demand
3.2 Largest Application for Radiopharmaceutical (Oral Route) (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Radiopharmaceutical (Oral Route) Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Radiopharmaceutical (Oral Route) Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Radiopharmaceutical (Oral Route) Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Radiopharmaceutical (Oral Route) Average Price Trend
12.1 Market Price for Each Type of Radiopharmaceutical (Oral Route) in US (2018-2022)
12.2 Market Price for Each Type of Radiopharmaceutical (Oral Route) in Europe (2018-2022)
12.3 Market Price for Each Type of Radiopharmaceutical (Oral Route) in China (2018-2022)
12.4 Market Price for Each Type of Radiopharmaceutical (Oral Route) in Japan (2018-2022)
12.5 Market Price for Each Type of Radiopharmaceutical (Oral Route) in India (2018-2022)
12.6 Market Price for Each Type of Radiopharmaceutical (Oral Route) in Korea (2018-2022)
12.7 Market Price for Each Type of Radiopharmaceutical (Oral Route) in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Radiopharmaceutical (Oral Route) Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Radiopharmaceutical (Oral Route)
14. Radiopharmaceutical (Oral Route) Competitive Landscape
14.1 Bracco Imaging
14.1.1 Bracco Imaging Company Profiles
14.1.2 Bracco Imaging Product Introduction
14.1.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Bayer
14.2.1 Bayer Company Profiles
14.2.2 Bayer Product Introduction
14.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Mallinckrodt
14.3.1 Mallinckrodt Company Profiles
14.3.2 Mallinckrodt Product Introduction
14.3.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Nordion
14.4.1 Nordion Company Profiles
14.4.2 Nordion Product Introduction
14.4.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Triad Isotopes
14.5.1 Triad Isotopes Company Profiles
14.5.2 Triad Isotopes Product Introduction
14.5.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Lantheus
14.6.1 Lantheus Company Profiles
14.6.2 Lantheus Product Introduction
14.6.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 IBA Group
14.7.1 IBA Group Company Profiles
14.7.2 IBA Group Product Introduction
14.7.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 GE Healthcare
14.8.1 GE Healthcare Company Profiles
14.8.2 GE Healthcare Product Introduction
14.8.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 China Isotope & Radiation
14.9.1 China Isotope & Radiation Company Profiles
14.9.2 China Isotope & Radiation Product Introduction
14.9.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Jubilant Pharma
14.10.1 Jubilant Pharma Company Profiles
14.10.2 Jubilant Pharma Product Introduction
14.10.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Eli Lilly
14.12 Advanced Accelerator Applications
14.13 SIEMENS
14.14 Dongcheng
14.15 Navidea
15. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
